Login to Your Account



The right direction: True North raises $40M series C round

By Michael Fitzhugh
Staff Writer

Thursday, December 3, 2015

True North Therapeutics Inc. raised $40 million in series C equity funding to advance development of its lead complement inhibitor, TNT009, through potential registration-enabling studies for cold agglutinin disease (CAD), while also advancing other complement inhibitors in its pipeline.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription